solcitinib
Small moleculeexperimental
Clinical trial activity
7 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2010 (NCT01278108)
Timeline
Indications
Mechanism of action
- Tyrosine-protein kinase JAK1INHIBITOR
JAK1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC1(C)CN(C(=O)c2ccc(-c3cccc4nc(NC(=O)C5CC5)nn34)cc2)C1- Mol. weight
- 389.46 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3301606 ↗
Also known as
- g-154578
- g-154578
- glpg0778
- glpg0778
- glpg-0778
- glpg-0778
- glpg-0788
- glpg-0788
- gsk2586184
- gsk2586184
- gsk2586184
- gsk2586184a
- gsk2586184a
- solcitinib
- solcitinib
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02000453 | Phase 1 | Dec 20, 2013 | GlaxoSmithKline, University of Amsterdam |
| NCT01953835 | Phase 1 | Oct 4, 2013 | GlaxoSmithKline |
| NCT01777256 | Phase 2 | Mar 1, 2013 | GlaxoSmithKline |
| NCT01782664 | Phase 2 | Mar 1, 2013 | GlaxoSmithKline |
| NCT01687309 | Phase 1 | Apr 30, 2012 | GlaxoSmithKline |
| NCT01336244 | Phase 1 | Apr 1, 2011 | Galapagos NV, SGS Life Sciences |
| NCT01278108 | Phase 1 | Dec 1, 2010 | Galapagos NV, SGS Life Sciences |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 5 | 5 | 2 | 2012 |
| Galapagos NV | For profit | 2 | 2 | 1 | 2010 |
| SGS Life Sciences | For profit | 2 | 0 | 1 | 2010 |
| University of Amsterdam | Academic/Hospital | 1 | 0 | 1 | 2013 |
4 organizations
Page 1 / 1